fig1

Figure 1. Screening of a small molecule compound library shows that Ivosidenib enhances the sensitivity of ovarian cancer cells to cisplatin. (A) Breakdown of the compound library based on the molecular pathways associated with the compound targets. (B) Dose-response curves for SK-3rd and SKDDP treated with cisplatin for 72 h. (C) Schematic of the compound screening.(D) Scatter plot showing cell viability in SK-3rd cells treated with compound library alone or the compound library + cisplatin. The red dots represent agents that resulted in over 90% survival of SK-3rd cells alone but less than 60% survival when combined with cisplatin (n = 4). (E) Corresponding compound names, concentrations, and cell viability data of compounds with > 90% cell viability when used alone but < 60% cell viability combined with 10 µM cisplatin.(F) Scatter plot showing cell viability in SKDDP cells treated with the five selected compounds alone or with the compounds plus cisplatin at a concentration of 10 µM (n = 4).